3rd Quarter - Termination

ARENTFOX SCHIFF LLP for KEMPHARM, INC.

Firm
Client
Income
$10,000
Expenses
—
Terminated
Jul 31, 2018

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

FDA regulation of opioid abuse deterrent formulations

LobbyistCovered position, as disclosed
PHILIP ENGLISH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse deterrent legislation H.R. 6 (SUPPORT for Patients and Communities Act), provisions relating to HHS study on abuse deterrent formulations access barriers under Medicare H.R. 5582 (Abuse Deterrent Access Act of 2018), all provisions Pharmaceutical anti-opioid prodrug regulatory bill

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
NORMAN FREDERICK LENT —
SONJA NESBIT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5582 (115th), H.R. 6 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.